| Literature DB >> 30044444 |
Zhenni Zhu1, Fan Wu2, Ye Lu3, Zhengyuan Wang4, Jiajie Zang5, Huiting Yu6, Changyi Guo7, Xiaodong Jia8, Xianbiao Shen9, Gangqiang Ding10.
Abstract
BACKGROUND: The associations between dietary cholesterol and fatty acids and serum lipids are controversial. This study is to examine the association of dietary cholesterol and fatty acids with serum lipids and dyslipidemia in Chinese metropolitan male and female adults.Entities:
Keywords: dietary cholesterol; dietary fatty acids; dyslipidemia; population-based epidemiology; serum lipids
Mesh:
Substances:
Year: 2018 PMID: 30044444 PMCID: PMC6115945 DOI: 10.3390/nu10080961
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
STROBE Checklist—cross-sectional studies.
| Item No | Recommendation | Check Notes by the Author | |
|---|---|---|---|
|
| 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | (a) A descriptive statement was revised instead of the previous definitive one. |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | (b) Conclusive statements in the abstract were revised to use appropriate language for observational studies. | ||
|
|
| ||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Background and rationale were clearly explained. |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Objectives were stated. A sentence was revised according to appropriate describing of observational studies. |
|
|
| ||
| Study design | 4 | Present key elements of study design early in the paper | Clearly stated the design of present study. |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Described the setting, locations, and relevant dates. Described there was no settings that might affect the dietary intake or nutritional status of the participants. |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants | (a) The criteria and methods of selection of participants were reported. |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Defined all outcomes, dietary intake, predictors and potential confounders. Dyslipidaemia definition was given. |
| Data sources/measurement | 8 * | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | The sources of data and details of methods of dietary and laboratory measurements were given. |
| Bias | 9 | Describe any efforts to address potential sources of bias | Described potential confounders and their assessment. |
| Study size | 10 | Explain how the study size was arrived at | Explained the study size and the size of the participants’ data used in current study were given. |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Explaind the reasonable scope of the quantitative variables (energy intakes) and the data within the scope were chosen. |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | (a) Described all statistical methods, including those used to control for confounding |
| (b) Describe any methods used to examine subgroups and interactions | (b) Described methods used to examine subgroups | ||
| (c) Explain how missing data were addressed | (c) Explained in the study population that the records with missing data were excluded. | ||
| (d) If applicable, describe analytical methods taking account of sampling strategy | (d) Described estimation and on ICC considering the sampling and decision on using fixed models. | ||
| (e) Describe any sensitivity analyses | (e) Described covariates selection procedure and the parameters setting. | ||
|
|
| ||
| Participants | 13 * | (a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | (a) Reported numbers of individuals’ in the current analysis. The number of individuals at each stage of study was reported in the methods part. |
| (b) Give reasons for non-participation at each stage | (b) Gave reasons for non-participation at each stage in the methods part. | ||
| (c) Consider use of a flow diagram | (c) Not using flow diagram. | ||
| Descriptive data | 14 * | (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders | (a) Gave characteristics of study participants and information on potential confounders. |
| (b) Indicate number of participants with missing data for each variable of interest | (b) Records with missing data were excluded. | ||
| Outcome data | 15 * | Report numbers of outcome events or summary measures | Reported serum lipids level and numbers of dyslipidaemia. |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included | (a) Gave confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Stated confounders adjusted for. The covariates selection was explained in the methods part. |
| (b) Report category boundaries when continuous variables were categorized | (b) Reported the dietary cholesterol category boundaries when it was categorized in the logistic regression model. | ||
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | |||
| Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | Reported the analyses of sex subgroups. |
|
|
| ||
| Key results | 18 | Summarise key results with reference to study objectives | Summarised key results with reference to study objectives. |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Discussed four limitations of the current study and potential bias or imprecision. |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Gave a cautious overall interpretation of results in the descriptive statements. |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Discussed the consistency and inconsistency with other studies. |
|
|
| ||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Gave the source of funding and the role of the funders for the present study. |
* Give information separately for exposed and unexposed groups. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
Characteristics of participants by sex in SDHS 2012–2013.
| All | Male | Female | ||
|---|---|---|---|---|
| 3850 (100.0) | 1838 (47.7) | 2012 (52.3) | ||
| Age, % | 0.513 | |||
| 18–44 years | 31.3 | 30.7 | 32.0 | |
| 45–49 years | 35.4 | 35.2 | 35.6 | |
| 60 years | 33.3 | 34.1 | 32.5 | |
| Ethnicity, % | 0.050 | |||
| Hans (ethnic majority) | 99.5 | 99.7 | 99.2 | |
| Other minorities | 0.5 | 0.3 | 0.8 | |
| Years of education, % | <0.001 | |||
| ≤9 years | 53.9 | 49.4 | 58.1 | |
| 9–12 years | 23.9 | 26.1 | 21.9 | |
| >12 years | 22.2 | 24.6 | 20.0 | |
| Yearly Income,% | 0.523 | |||
| Above average level (>60,000 RMB) | 7.8 | 7.3 | 8.2 | |
| Average level (30,000–59,999 RMB) | 30.9 | 32.2 | 29.9 | |
| Below average level (<30,000 RMB) | 56.8 | 55.8 | 57.7 | |
| No answer | 4.5 | 4.8 | 4.2 | |
| Smoking Status, % | <0.001 | |||
| Never smoker | 71.0 | 41.0 | 98.8 | |
| Former smoker | 5.4 | 10.8 | 0.4 | |
| Current smoker | 23.6 | 48.3 | 0.8 | |
| Physical Activity Level, % | <0.001 | |||
| Sedentary | 84.5 | 79.4 | 89.0 | |
| Moderate | 13.6 | 17.5 | 10.1 | |
| Vigorous | 2.0 | 3.1 | 0.9 | |
| Dietary intake | ||||
| Energy, kcal/day (SE 1) | 1679.0 (9.2) | 1826.2 (13.3) | 1542.9 (12.1) | <0.0001 |
| Carbohydrate, g/day (SE) | 198.0 (1.3) | 212.4 (1.9) | 184.6 (1.7) | <0.0001 |
| Protein, g/day (SE) | 64.0 (0.4) | 69.3 (0.7) | 59.1 (0.6) | <0.0001 |
| Total fat, g/day (SE) | 71.5 (0.6) | 77.9 (0.9) | 65.8 (0.8) | <0.0001 |
| SFAs 1, g/day (SE) | 15.4 (0.1) | 16.7 (0.2) | 14.2 (0.2) | <0.0001 |
| MUFAs 1, g/day (SE) | 26.0 (0.2) | 28.6 (0.4) | 23.7 (0.3) | <0.0001 |
| PUFAs 1, g/day (SE) | 20.9 (0.2) | 22.6 (0.4) | 19.3 (0.3) | <0.0001 |
| Dietary cholesterol, mg/day (SE) | 377.8 (3.5) | 399.1 (5.1) | 358.0 (4.8) | <0.0001 |
| BMI 1 (kg/m2), % | <0.001 | |||
| Underweight (<18.5) | 4.4 | 3.8 | 4.9 | |
| Normal weight (18.5–23.9) | 49.5 | 45.1 | 53.6 | |
| Overweight (24.0–27.9) | 35.2 | 39.9 | 30.8 | |
| Obese (≥28.0) | 11.0 | 11.2 | 10.8 | |
| Serum lipids profile | ||||
| TC, mg/dL (SE) 1 | 182.9 (0.6) | 179.1 (0.8) | 186.3 (0.8) | <0.001 |
| LDL-C, mg/dL (SE) 1 | 112.2 (0.6) | 111.5 (0.8) | 112.9 (0.8) | <0.001 |
| HDL-C, mg/dL (SE) 1 | 56.5 (0.3) | 53.5 (0.4) | 59.2 (0.4) | <0.001 |
| Triglycerides, mg/dL (SE) | 133.5 (1.8) | 145.8 (2.9) | 122.1 (2.3) | <0.001 |
| Dyslipidemia 2 | ||||
| High TC, % | 5.8 | 4.0 | 7.4 | <0.001 |
| High LDL-C, % | 7.6 | 6.4 | 8.6 | 0.027 |
| Low HDL-C, % | 20.9 | 14.8 | 26.3 | <0.001 |
| High triglycerides, % | 27.3 | 31.3 | 23.6 | <0.001 |
1 SE, standard errors; SFAs, saturated fatty acids; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; TC, total cholesterol; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; BMI, Body mass index. 2 Dyslipidemia was determined as high TC: serum TC ≥ 240 mg/dL; high LDL-C: serum LDL ≥ 160 mg/dL; low HDL-C: serum HDL-C < 40 mg/dL in men or < 50 mg/dL in women; high triglycerides: serum triglycerides ≥150 mg/dL.
General linear regression between dietary cholesterol and fatty acids intake and serum cholesterol and triglycerides level in SDHS 2012–2013 1.
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| |
|
| |||||||||
| Cholesterol | 0.64 | (0.13, 1.15) | 0.015 | 0.73 | (0.21,1.24) | 0.006 | 0.15 | (−0.08, 0.38) | 0.213 |
| SFAs | 0.81 | (−0.68, 2.29) | 0.287 | 0.37 | (−1.17, 1.90) | 0.641 | 0.51 | (−0.18, 1.19) | 0.145 |
| MUFAs | 0.53 | (−0.28, 1.35) | 0.200 | 0.07 | (−0.77, 0.92) | 0.863 | 0.32 | (−0.05, 0.70) | 0.093 |
| PUFAs | 0.06 | (−0.74, 0.85) | 0.892 | 0.35 | (−0.47, 1.16) | 0.403 | 0.33 | (−0.03, 0.69) | 0.075 |
|
| |||||||||
| Cholesterol | 0.27 | (−0.45, 1.00) | 0.459 | 0.43 | (−0.29, 1.16) | 0.239 | 0.00 | (−0.32, 0.32) | 0.995 |
| SFAs | 0.94 | (−1.06, 2.95) | 0.357 | 0.80 | (−1.29, 2.88) | 0.454 | 0.32 | (−0.61, 1.25) | 0.501 |
| MUFAs | 0.65 | (−0.44, 1.73) | 0.242 | 0.45 | (−0.67, 1.57) | 0.431 | 0.29 | (−0.22, 0.79) | 0.264 |
| PUFAs | 0.48 | (−0.58, 1.53) | 0.375 | 0.71 | (−0.37, 1.79) | 0.199 | 0.34 | (−0.14, 0.82) | 0.169 |
|
| |||||||||
| Cholesterol | 0.97 | (0.25, 1.68) | 0.008 | 0.94 | (0.22, 1.67) | 0.011 | 0.35 | (0.02, 0.67) | 0.036 |
| SFAs | 0.45 | (−1.74, 2.63) | 0.689 | −0.44 | (−2.67, 1.80) | 0.701 | 0.85 | (−0.14, 1.84) | 0.094 |
| MUFAs | 0.33 | (−0.88, 1.55) | 0.593 | −0.49 | (−1.75, 0.77) | 0.445 | 0.41 | (−0.15, 0.97) | 0.147 |
| PUFAs | −0.45 | (−1.64, 0.75) | 0.463 | −0.18 | (−1.40, 1.04) | 0.775 | 0.33 | (−0.21, 0.88) | 0.227 |
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| |
|
| |||||||||
| Cholesterol | 0.01 | (0.00, 0.02) | 0.018 | 0.01 | (−0.01, 0.03) | 0.304 | 0.77 | (−0.90, 2.45) | 0.364 |
| SFA | 0.00 | (−0.04, 0.03) | 0.801 | −0.03 | (−0.08, 0.02) | 0.242 | −2.49 | (−7.34, 2.36) | 0.314 |
| MUFA | −0.01 | (−0.03, 0.01) | 0.318 | −0.02 | (−0.04, 0.01) | 0.226 | −0.73 | (−3.38, 1.92) | 0.589 |
| PUFA | −0.01 | (−0.02, 0.01) | 0.513 | −0.02 | (−0.05, 0.00) | 0.092 | −1.88 | (−4.48, 0.72) | 0.156 |
|
| |||||||||
| Cholesterol | 0.01 | (−0.01, 0.03) | 0.206 | 0.01 | (−0.02, 0.03) | 0.632 | 0.38 | (−2.18, 2.94) | 0.771 |
| SFA | 0.00 | (−0.04, 0.05) | 0.888 | −0.03 | (−0.10, 0.04) | 0.441 | −3.91 | (−11.01, 3.19) | 0.280 |
| MUFA | 0.00 | (−0.03, 0.02) | 0.810 | −0.02 | (−0.05, 0.02) | 0.435 | −1.52 | (−5.36, 2.32) | 0.437 |
| PUFA | 0.00 | (−0.03, 0.02) | 0.897 | −0.02 | (−0.05, 0.02) | 0.416 | −1.41 | (−5.15, 2.33) | 0.460 |
|
| |||||||||
| Cholesterol | 0.01 | (0.00, 0.03) | 0.093 | 0.01 | (−0.02, 0.03) | 0.527 | 0.93 | (−1.19, 3.06) | 0.390 |
| SFA | −0.02 | (−0.07, 0.02) | 0.304 | −0.04 | (−0.11, 0.02) | 0.201 | −1.70 | (−8.16, 4.75) | 0.605 |
| MUFA | −0.02 | (−0.05, 0.00) | 0.114 | −0.02 | (−0.06, 0.02) | 0.248 | 0.04 | (−3.55, 3.63) | 0.984 |
| PUFA | −0.01 | (−0.04, 0.01) | 0.303 | −0.03 | (−0.07, 0.00) | 0.075 | −2.25 | (−5.78, 1.28) | 0.211 |
1 General linear regression models were used to estimate β and 95% CIs adjusted by age (continuous), sex (male, female), BMI (continuous) and smoking statuses (never smoker, former smoker, current smoker). When stratified by sex, models were adjusted by age, BMI and smoking statuses. 2 β represents the partial correlation coefficients in the model, which means the increase (mg/dL) of serum cholesterol or triglycerides by each additional 100 mg dietary cholesterol intake or 10 g dietary fatty acids intake.
ORs (95% CI) for dyslipidemia according to the quintiles of dietary cholesterol intake (mg/day) in SDHS 2012–2013 1.
| Quintiles of Dietary Cholesterol Intake (mg/day) | ||||||
|---|---|---|---|---|---|---|
| Q1 (<193.1) | Q2 (193.1–293.0) | Q3 (293.1–401.6) | Q4 (401.7–529.9) | Q5 (≥538.0) | ||
|
| ||||||
|
| 770 | 770 | 770 | 770 | 770 | |
| High TC | OR | Reference | 1.19 | 1.33 | 1.14 | 1.57 |
| 95% CI | (0.76, 1.87) | (0.85, 2.08) | (0.71, 1.81) | (1.01, 2.43) | ||
| 0.448 | 0.210 | 0.585 | 0.044 | |||
| High LDL-C | OR | Reference | 0.98 | 1.04 | 1.10 | 1.59 |
| 95% CI | (0.63, 1.54) | (0.66, 1.64) | (0.70, 1.74) | (1.05, 2.42) | ||
| 0.931 | 0.858 | 0.666 | 0.030 | |||
| Low HDL-C | OR | Reference | 0.99 | 0.85 | 1.03 | 0.83 |
| 95% CI | (0.75, 1.30) | (0.64, 1.13) | (0.78, 1.36) | (0.62, 1.11) | ||
| 0.914 | 0.256 | 0.843 | 0.207 | |||
| High triglyceride | OR | Reference | 1.05 | 0.88 | 1.04 | 1.21 |
| 95% CI | (0.83, 1.33) | (0.69, 1.12) | (0.82, 1.32) | (0.96, 1.53) | ||
| 0.681 | 0.304 | 0.741 | 0.111 | |||
|
| ||||||
|
| 316 | 342 | 359 | 409 | 412 | |
| High TC | OR | Reference | 1.47 | 1.40 | 0.73 | 1.51 |
| 95% CI | (0.64, 3.34) | (0.61, 3.17) | (0.29, 1.82) | (0.69, 3.32) | ||
| 0.361 | 0.426 | 0.494 | 0.305 | |||
| High LDL-C | OR | Reference | 0.90 | 1.00 | 0.81 | 1.27 |
| 95% CI | (0.43, 1.87) | (0.49, 2.03) | (0.39, 1.69) | (0.66, 2.45) | ||
| 0.777 | 0.992 | 0.583 | 0.478 | |||
| Low HDL-C | OR | Reference | 1.03 | 0.85 | 0.73 | 0.82 |
| 95% CI | (0.65, 1.65) | (0.53, 1.39) | (0.45, 1.19) | (0.52, 1.31) | ||
| 0.892 | 0.525 | 0.202 | 0.411 | |||
| High triglyceride | OR | Reference | 1.38 | 1.01 | 1.15 | 1.33 |
| 95% CI | (0.97, 1.97) | (0.70, 1.44) | (0.81, 1.62) | (0.95, 1.87) | ||
| 0.072 | 0.978 | 0.436 | 0.100 | |||
|
| ||||||
|
| 454 | 428 | 411 | 361 | 358 | |
| High TC | OR | Reference | 1.05 | 1.31 | 1.38 | 1.56 |
| 95% CI | (0.61, 1.81) | (0.77, 2.25) | (0.80, 2.37) | (0.91, 2.67) | ||
| 0.855 | 0.322 | 0.247 | 0.104 | |||
| High LDL-C | OR | Reference | 1.00 | 1.05 | 1.33 | 1.84 |
| 95% CI | (0.56, 1.77) | (0.58, 1.89) | (0.75, 2.38) | (1.07, 3.16) | ||
| 0.998 | 0.882 | 0.332 | 0.027 | |||
| Low HDL-C | OR | Reference | 0.96 | 0.86 | 1.29 | 0.82 |
| 95% CI | (0.68, 1.35) | (0.60, 1.23) | (0.91, 1.83) | (0.57, 1.19) | ||
| 0.815 | 0.414 | 0.157 | 0.303 | |||
| High triglyceride | OR | Reference | 0.84 | 0.83 | 1.01 | 1.18 |
| 95% CI | (0.60, 1.16) | (0.59, 1.16) | (0.72, 1.41) | (0.85, 1.65) | ||
| 0.287 | 0.272 | 0.969 | 0.328 | |||
1 Multivariate binomial logistic regression models were used to estimate ORs and 95% CIs adjusted by age (continuous), sex (male, female), BMI (continuous) and smoking statuses (never smoker, former smoker, current smoker). When stratified by sex, models were adjusted by age, BMI and smoking statuses.